Literature DB >> 24067378

Psychosocial aspects of systemic sclerosis.

Vanessa L Malcarne1, Rina S Fox, Sarah D Mills, Shadi Gholizadeh.   

Abstract

PURPOSE OF REVIEW: In 2010, an international consortium of researchers published a consensus agenda for research on psychosocial aspects of systemic sclerosis (SSc; scleroderma). The present review summarizes recent research on SSc-related depression and anxiety, fatigue and sleep, pain, pruritus, body image distress, sexual function, work disability, healthcare needs, psychosocial interventions, and psychoneuroimmunology. RECENT
FINDINGS: Researchers have used structured interviews to establish prevalence rates for clinical mood disorders in SSc, although anxiety remains understudied and distress may be a useful outcome to consider. Longitudinal research has identified predictors of fatigue. Research on body image distress suggests the importance of changes in the facial skin and hands. Studies have identified sexual function problems in women and men with SSc. A prospective study found that breathing problems and fatigue predicted workplace disability. A randomized controlled trial evaluating multidisciplinary care showed benefits for health-related quality of life.
SUMMARY: There has been a recent expansion in studies of psychosocial aspects of SSc, and in the validation of psychosocial measures that can be used in clinics to identify problems and track outcomes; however, prospective studies remain scarce. To better address the psychosocial needs of persons with SSc, interventions need to be developed and tested via randomized controlled trials with power to detect clinically meaningful changes.

Entities:  

Mesh:

Year:  2013        PMID: 24067378     DOI: 10.1097/01.bor.0000434666.47397.c2

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  10 in total

1.  Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study.

Authors:  Sarah D Mills; Rina S Fox; Erin L Merz; Philip J Clements; Suzanne Kafaja; Vanessa L Malcarne; Daniel E Furst; Dinesh Khanna
Journal:  J Rheumatol       Date:  2015-06-01       Impact factor: 4.666

2.  Olfactory impairment in patients with the fibromyalgia syndrome and systemic sclerosis.

Authors:  Howard Amital; Nancy Agmon-Levin; Netta Shoenfeld; Yoav Arnson; Daniela Amital; Pnina Langevitz; Alexandra Balbir Gurman; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Validation of the Social Interaction Anxiety Scale in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort study.

Authors:  Shadi Gholizadeh; Linda Kwakkenbos; Marie-Eve Carrier; Sarah D Mills; Rina S Fox; Lisa R Jewett; Karen Gottesman; Scott Roesch; Brett D Thombs; Vanessa L Malcarne
Journal:  J Scleroderma Relat Disord       Date:  2017-10-24

4.  Coping profiles and health outcomes among individuals with systemic sclerosis: A latent profile analysis approach.

Authors:  Shelley E Condon; Scott C Roesch; Philip J Clements; Daniel E Furst; Michael H Weisman; Vanessa L Malcarne
Journal:  J Scleroderma Relat Disord       Date:  2020-06-22

5.  Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life Study.

Authors:  Rina S Fox; Sarah D Mills; Shadi Gholizadeh; Erin L Merz; Scott C Roesch; Philip J Clements; Suzanne Kafaja; Dinesh Khanna; Daniel E Furst; Vanessa L Malcarne
Journal:  J Scleroderma Relat Disord       Date:  2019-12-22

6.  The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients.

Authors:  Brooke Levis; Linda Kwakkenbos; Marie Hudson; Murray Baron; Brett D Thombs
Journal:  Clin Rheumatol       Date:  2016-12-10       Impact factor: 2.980

7.  The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial.

Authors:  George P Karamanolis; Stylianos Panopoulos; Konstantinos Denaxas; Anastasios Karlaftis; Alexandra Zorbala; Dimitrios Kamberoglou; Spiros D Ladas; Petros P Sfikakis
Journal:  Arthritis Res Ther       Date:  2016-09-01       Impact factor: 5.156

8.  Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating 'not applicable' responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study.

Authors:  Erin L Merz; Linda Kwakkenbos; Marie-Eve Carrier; Shadi Gholizadeh; Sarah D Mills; Rina S Fox; Lisa R Jewett; Heidi Williamson; Diana Harcourt; Shervin Assassi; Daniel E Furst; Karen Gottesman; Maureen D Mayes; Tim P Moss; Brett D Thombs; Vanessa L Malcarne
Journal:  BMJ Open       Date:  2018-03-06       Impact factor: 2.692

9.  Effect of a tailored home-based exercise program in patients with systemic sclerosis: A randomized controlled trial.

Authors:  Mirko Filippetti; Lucia Cazzoletti; Francesco Zamboni; Pietro Ferrari; Cristian Caimmi; Nicola Smania; Stefano Tardivo; Marcello Ferrari
Journal:  Scand J Med Sci Sports       Date:  2020-05-11       Impact factor: 4.221

Review 10.  The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis.

Authors:  Nicola Farina; Giovanni Benanti; Giacomo De Luca; Anna Palmisano; Giovanni Peretto; Sara Tomassetti; Veronica Giorgione; Ornella Forma; Antonio Esposito; Silvio Danese; Lorenzo Dagna; Marco Matucci-Cerinic; Corrado Campochiaro
Journal:  J Multidiscip Healthc       Date:  2022-04-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.